Tags

Type your tag names separated by a space and hit enter

Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers.
J Clin Pharmacol. 2020 Jun; 60(6):734-743.JC

Abstract

Eosinophilic esophagitis is a common atopic disease of the esophagus. APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate under development for the treatment of eosinophilic esophagitis. The objective of this study was to evaluate the pharmacokinetics, safety, and tolerability of APT-1011 under fed or fasted conditions in the morning (am) or at bedtime (hs) in the supine position. The study was a randomized, single-dose, 3-way, crossover design in healthy adult volunteers. In each study period participants received 2 3-mg orally disintegrating APT-1011 tablets. Serial plasma samples were collected before dosing and up to 72 hours after each dose. Twenty-two participants completed the study. The fluticasone propionate peak concentration (Cmax) ranged from 5.97 to 200 pg/mL. Compared with am-fasted dosing, am-fed dosing was associated with a modestly higher Cmax (∼21%) but lower net exposure (area under the concentration-time curve ∼56% difference) and shorter time to reach Cmax (Tmax) (Tmax fasted = 10 hours, fed = 5 hours). Dosing at hs resulted in an 18% and 32% decrease in Cmax relative to am-fasted and am-fed conditions, respectively. Dosing at hs led to an exposure that was higher than am-fed but lower than am-fasted dosing. Tmax with hs dosing (14 hours) was later than that with am dosing (Tmax fasted = 10 hours, fed = 5 hours). Adverse events were mild. There is low systemic exposure of fluticasone propionate with APT-1011. The rate of absorption was increased with a high-fat meal but decreased with hs dosing, suggesting the potential for longer dwell times in the esophagus.

Authors+Show Affiliations

Adare Pharmaceuticals, Lawrence Township, New Jersey, USA.Nuventra Pharma Sciences, Durham, North Carolina, USA.Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.Mark T. Marino, Consulting, LLC, Carlsbad, California, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31943257

Citation

Comer, Gail M., et al. "Effect of Food Intake and Body Position On the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers." Journal of Clinical Pharmacology, vol. 60, no. 6, 2020, pp. 734-743.
Comer GM, Bush MA, Dellon ES, et al. Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. J Clin Pharmacol. 2020;60(6):734-743.
Comer, G. M., Bush, M. A., Dellon, E. S., & Marino, M. T. (2020). Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. Journal of Clinical Pharmacology, 60(6), 734-743. https://doi.org/10.1002/jcph.1572
Comer GM, et al. Effect of Food Intake and Body Position On the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. J Clin Pharmacol. 2020;60(6):734-743. PubMed PMID: 31943257.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. AU - Comer,Gail M, AU - Bush,Mark A, AU - Dellon,Evan S, AU - Marino,Mark T, Y1 - 2020/01/15/ PY - 2019/10/02/received PY - 2019/12/02/accepted PY - 2020/1/17/pubmed PY - 2020/1/17/medline PY - 2020/1/17/entrez KW - APT-1011 KW - bedtime dosing KW - eosinophilic esophagitis KW - fluticasone propionate KW - orally disintegrating tablet KW - pharmacokinetics KW - topical SP - 734 EP - 743 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 60 IS - 6 N2 - Eosinophilic esophagitis is a common atopic disease of the esophagus. APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate under development for the treatment of eosinophilic esophagitis. The objective of this study was to evaluate the pharmacokinetics, safety, and tolerability of APT-1011 under fed or fasted conditions in the morning (am) or at bedtime (hs) in the supine position. The study was a randomized, single-dose, 3-way, crossover design in healthy adult volunteers. In each study period participants received 2 3-mg orally disintegrating APT-1011 tablets. Serial plasma samples were collected before dosing and up to 72 hours after each dose. Twenty-two participants completed the study. The fluticasone propionate peak concentration (Cmax) ranged from 5.97 to 200 pg/mL. Compared with am-fasted dosing, am-fed dosing was associated with a modestly higher Cmax (∼21%) but lower net exposure (area under the concentration-time curve ∼56% difference) and shorter time to reach Cmax (Tmax) (Tmax fasted = 10 hours, fed = 5 hours). Dosing at hs resulted in an 18% and 32% decrease in Cmax relative to am-fasted and am-fed conditions, respectively. Dosing at hs led to an exposure that was higher than am-fed but lower than am-fasted dosing. Tmax with hs dosing (14 hours) was later than that with am dosing (Tmax fasted = 10 hours, fed = 5 hours). Adverse events were mild. There is low systemic exposure of fluticasone propionate with APT-1011. The rate of absorption was increased with a high-fat meal but decreased with hs dosing, suggesting the potential for longer dwell times in the esophagus. SN - 1552-4604 UR - https://www.unboundmedicine.com/medline/citation/31943257/Effect_of_Food_Intake_and_Body_Position_on_the_Pharmacokinetics_of_Swallowed_APT-1011,_a_Fluticasone_Orally_Disintegrating_Tablet,_in_Healthy_Adult_Volunteers L2 - https://doi.org/10.1002/jcph.1572 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.